Form 4: CYTK Director Sells Shares Under 10b5-1 Plan

Cytokinetics Director Edward M. Kaye MD sold 6,757 shares of common stock at $60 per share, reducing his direct beneficial ownership to 9,778 shares, pursuant to a Rule 10b5-1 plan.

Summary

• Edward M. Kaye MD, a Director of Cytokinetics Inc. (CYTK), reported a sale of common stock.
• The transaction involved the disposition of 6,757 shares of common stock.
• The shares were sold at a price of $60 per share.
• The transaction occurred on October 6, 2025.
• Following this transaction, Dr. Kaye directly beneficially owns 9,778 shares of Cytokinetics common stock.
• The sale was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The transaction is a pre-planned sale under a Rule 10b5-1 plan, which is typically a neutral event for market sentiment as it often relates to personal financial management rather than a change in outlook on the company's prospects.

Future Outlook

This Form 4 filing reports an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports a routine insider transaction under a pre-arranged plan, which is a common practice for corporate executives and directors for personal financial planning. It does not provide insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale by a director could be perceived as a minor signal, though its execution under a 10b5-1 plan mitigates concerns about immediate sentiment. The total value of the sale is approximately $405,420.

Key Dates

Keywords

Cytokinetics, CYTK, Form 4, Insider Trading, Director Sale, Stock Transaction, 10b5-1 Plan